Literature DB >> 22337094

BCR-ABL signaling: A new STATus in CML.

Doriano Fabbro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22337094     DOI： 10.1038/nchembio.900

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  13 in total

1.  STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.

Authors:  C Sillaber; F Gesbert; D A Frank; M Sattler; J D Griffin
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

2.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors:  Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

3.  An efficient rapid system for profiling the cellular activities of molecular libraries.

Authors:  Jonathan S Melnick; Jeff Janes; Sungjoon Kim; Jim Y Chang; Daniel G Sipes; Drew Gunderson; Laura Jarnes; Jason T Matzen; Michael E Garcia; Tami L Hood; Ronak Beigi; Gang Xia; Richard A Harig; Hayk Asatryan; S Frank Yan; Yingyao Zhou; Xiang-Ju Gu; Alham Saadat; Vicki Zhou; Frederick J King; Christopher M Shaw; Andrew I Su; Robert Downs; Nathanael S Gray; Peter G Schultz; Markus Warmuth; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

4.  Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Authors:  Doriano Fabbro; Paul W Manley; Wolfgang Jahnke; Janis Liebetanz; Alexandra Szyttenholm; Gabriele Fendrich; Andre Strauss; Jianming Zhang; Nathanael S Gray; Francisco Adrian; Markus Warmuth; Xavier Pelle; Robert Grotzfeld; Frederic Berst; Andreas Marzinzik; Sandra W Cowan-Jacob; Pascal Furet; Jürgen Mestan
Journal:  Biochim Biophys Acta       Date:  2010-03

5.  High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

Authors:  Wolfgang Warsch; Karoline Kollmann; Eva Eckelhart; Sabine Fajmann; Sabine Cerny-Reiterer; Andrea Hölbl; Karoline V Gleixner; Michael Dworzak; Matthias Mayerhofer; Gregor Hoermann; Harald Herrmann; Christian Sillaber; Gerda Egger; Peter Valent; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

6.  Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.

Authors:  S S Clark; J McLaughlin; W M Crist; R Champlin; O N Witte
Journal:  Science       Date:  1987-01-02       Impact factor: 47.728

7.  The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.

Authors:  Erik A Nelson; Sarah R Walker; Ellen Weisberg; Michal Bar-Natan; Rosemary Barrett; Laurie B Gashin; Shariya Terrell; Josephine L Klitgaard; Loredana Santo; Martha R Addorio; Benjamin L Ebert; James D Griffin; David A Frank
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

Review 8.  Current status of therapy for chronic myeloid leukemia: a review of drug development.

Authors:  Swami Padmanabhan; Saritha Ravella; Tyler Curiel; Francis Giles
Journal:  Future Oncol       Date:  2008-06       Impact factor: 3.404

Review 9.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

10.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.

Authors:  N Carlesso; D A Frank; J D Griffin
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307
View more
  3 in total

Review 1.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

2.  Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

Authors:  Mohamed El Missiry; Henrik Hjorth-Hansen; Johan Richter; Ulla Olson-Strömberg; Leif Stenke; Kimmo Porkka; Anna Kreutzman; Satu Mustjoki
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

3.  Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Authors:  Seiichi Okabe; Tetsuzo Tauchi; Seiichiro Katagiri; Yuko Tanaka; Kazuma Ohyashiki
Journal:  J Hematol Oncol       Date:  2014-04-28       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.